OPC-51803

DB05838ExperimentalSmall molecule

OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal... It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence.

Primary indication: Investigated for use/treatment in nocturia (frequent nighttime urination) and urinary incontinence.Curator reviewed
Formula / weight: C₂₆H₃₂ClN₃O₂ · 454.004 g/mol (avg)
Code names: OPC-51803

Resolves to

Compound

UNII1IGV6WTK9IChEMBLCHEMBL332447PubChem3038506

Structure

InChIKeyINGXCNVWWKKWOO-LJQANCHMSA-NSMILESCC(C)NC(=O)C[C@H]1CCCN(C(=O)C2=C(Cl)C=C(C=C2)N2CCCC2)C2=CC=CC=C12

Targets

P30518AVPR2

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with OPC-51803, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account